Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis

NCT00553943 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Lymphoma Study Association